ClinicalTrials.gg
RecruitingNCT07312435BOOMERANGUpdated Dec 31, 2025

B-vitamins and Omega-3 Fatty Acids and Biomarkers of Brain Atrophy.

An interventional study of Intervention and Control in Dementia and Cognitive Function, sponsored by University of Oslo. Recruiting at 1 site in Norway. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-31.

Sponsored by University of Oslo · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Sep 2025, registered Dec 2025).
  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 60 studies in Dementia with a site in Norway — 12 open to participants now, 15 under way, 1 of them phase 3. Dementia · Norway.

Planned enrollment
31st of 41
96 · median 212
Started
2025
with 4 others
No phase
28 of 60
2 open now
Primary completion
2027-03
later than 8 of 14 live
Registered
58th of 60
by date

Among the 60 studies in Dementia with a site in Norway, this one is the 31st largest by planned enrollment of the 41 interventional ones that give a count, is one of 5 that started in 2025, is one of 28 with no phase, reaches primary completion later than 8 of the 14 other live ones, and was the 58th registered.

Dementia

2,377 studies on the registry are indexed under Dementia; 572 are open to participants now.

Browse Dementia studies →

Open to participants now

12 of the 60 studies in Dementia with a site in Norway are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →

Who these studies take

Of the 382 Dementia studies recruiting now, 242 (63%) set no upper age limit and 25 (7%) stop at 75 or younger; 15 take children under 18; 163 take healthy volunteers.

This study: 65 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Dementia with a site in Norway, or all of them as a file.
02

Study summary

A poor nutrition status is a modifiable risk factor for cognitive decline and dementia. In particular, evidence links low status of certain B-vitamins and ω-3 fatty acids (ω-3 FA) with a greater risk of cognitive decline and dementia. Although these dietary components are typically investigated separately, post-hoc analyses of existing clinical trial data and experimental work indicate that B-vitamins and ω-3 FA may exert synergistic beneficial effects on processes related to brain health and cognition. However, this combination has not been tested directly in humans. In the proposed BOOMERANG project, we will study the effects of jointly supplementing with B-vitamins and a highly bioavailable ω-3 FA supplement, Lysoveta, on a robust biomarker of brain atrophy, the neurofilament light chain, in a double-blinded randomized controlled trial (RCT) over 3 months in older adults. We will also examine the secondary effects of the supplement of quality of life and cognitive function.

Read the detailed description

We will assess the effects of combined supplementation of B-vitamins and omega-3 fatty acids on neurofilament light chain (NfL), a biomarker of brain atrophy, in a group of older adults. The primary outcome is the change in plasma NfL, which is a marker related to inflammation, brain atrophy, and worsening of cognitive performance. The secondary outcomes are related to change in plasma homocysteine, B-vitamins, EPA, DHA, omega-3 index (the percentage of EPA and DHA in red blood cells), and biological age using epigenetic markers. These are biomarkers that can tell us about the effect of the supplement in the body. We also want to study the effect of the intervention on gene expression profiles and metabolite profiles. In addition, we will include secondary outcome measures of quality of life (SF-36) that include affective symptoms, as these can be a forerunner to developing cognitive impairment. We are also collecting data on their cognitive performance, as this is related to brain atrophy and neurological conditions.

03

Conditions studied

  • Dementia
  • Cognitive Function

Browse trials for

Keywords

  • Nutrition
  • Omega3
  • B vitamins
  • older adults
  • cognition
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age > 65 years
  • A low baseline B-vitamin status as assessed by plasma tHcy > 11 μmol/L
  • Normal score (>25)

Exclusion criteria

Exclusion Criteria:

  • Unable to give
  • Fatty fish intake > 2 times per week
  • daily omega-3 supplementation
  • daily B-vitamin supplementation
  • history of B12-injections
  • Serum creatinine > 90 μmol/L for women and > 105 μmol/L for men (above reference values)
  • aspirin use
  • renal disease
  • active cancer
  • Participants can be included if they accept to not take omega-3 supplementation or B-vitamin supplements during the study. They should stop using it and wait 12 weeks before they are invited to a screening visit.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
96 participants (estimated)

Study arms

  • Experimental
    Intervention

    The intervention group will receive daily supplementation of one pill of B-vitamins (0.5 mg B12, 0.8 mg folate, 10 mg B6 and 10 mg riboflavin) + six pills of 500 mg Lysoveta, in total 3 g Lysoveta (480 mg EPA, 240 mg DHA).

    Dietary Supplement: Intervention

  • Placebo comparator
    Control

    The control group will receive daily supplementation of one placebo pill matching the B-vitamins and one placebo pill matching Lysoveta.

    Other: Control

Interventions

  • Dietary supplementIntervention

    The intervention group will receive daily supplementation of one pill of B-vitamins (0.5 mg B12, 0.8 mg folate, 10 mg B6 and 10 mg riboflavin) + six pills of 500 mg Lysoveta, in total 3 g Lysoveta (480 mg EPA, 240 mg DHA). Lysoveta is an LPC-bound EPA/DHA supplement from krill which Aker BioMarine has recently developed.

  • OtherControl

    The control group will receive daily supplementation of one placebo pill matching the B-vitamins and one placebo pill matching Lysoveta. the placebo capsules will contain 500 mg of mixed vegetable oil (comprising a blend of olive-, maize-, and palm kernel oil and medium-chain triglycerides, in a ratio of 4:4:3:2)

06

What researchers measure

Primary outcomes

  1. Neurofilament light chain (NfL)

    To assess the effects of combined supplementation of B-vitamins and omega-3 fatty acids on neurofilament light chain (NfL), a biomarker of brain atrophy in a group of elderly

    Time frame: 3 months

Secondary outcomes

  1. Cognitive function

    Neuropsychological tests of global and domain specific cognitive functions will be assessed using a test battery that includes the Mini-Mental state Examination, Cognistat, and Cerad test battery (working memory, verbal fluency, constructional praxis).

    Time frame: 3 months

  2. Change in plasma homocysteine

    Change in plasma homocysteine

    Time frame: 3 months

  3. B-vitamins

    B-vitamins (B12, folate, B6 and riboflavin)

    Time frame: 3 months

  4. Omega-3

    EPA, DHA, omega-3 index (the percentage of EPA and DHA in red blood cells)

    Time frame: 3 months

Other outcomes

  1. Biological age

    Biological age using epigenetic clocks

    Time frame: 3 months

  2. Biomarkers of brain atrophy,

    p-tau, inflammation,

    Time frame: 3 months

  3. Quality of life in older adults

    Quality of life RAND SF-36

    Time frame: 3 months

  4. Transcriptome PBMC

    Biomarker

    Time frame: 3 months

  5. Metabolome in plasma

    Biomarker

    Time frame: 3 months

  6. Gut microbiome

    Biomarker

    Time frame: 3 months

07

Study locations

1 of 1 sites recruiting
  • Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo
    Oslo, Norway
    Recruiting
    • Stine Ulven, PhD · Contactsmulven@medisin.uio.no · +4722840208
    • Tahreem G Siddiqui, PhD · Contacttahreems@uio.no · +4722840208
    • Stine G Ulven, PhD · Principal investigator
    • Tahreem G Siddiqui, PhD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No — We are not allowed to share IP data due to the Univerity of Oslos data protection and regional ethical comittee rules.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Mar 2027, 18 months after the start.

Of 862 non-industry interventional studies with no phase under Dementia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 18 months is below that.

Counting every sponsor, half of 908 studies reached it within 25 months; a quarter within 11 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2025
First posted
Dec 31, 2025
StartActual
Sep 1, 2025
Primary completionEst.
Mar 1, 2027
CompletionEst.
Jun 1, 2028
Last update
Dec 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07312435
Lead sponsor
University of Oslo
Collaborators
Maastricht University, University of Dublin, Trinity College, Aker BioMarine, University of Ulster, Heinrich-Heine University, Duesseldorf
Responsible party
Stine Marie Ulven (Professor, University of Oslo) — Principal investigator
First posted
Dec 31, 2025
Start date
Sep 1, 2025
Primary completion
Mar 1, 2027 (estimated)
Completion
Jun 1, 2028 (estimated)
Last update
Dec 31, 2025

Study contacts

Stine M Ulven, PhD
Contact
smulven@medisin.uio.no
+4722840208
Tahreem G Siddiqui, PhD
Contact
tahreems@uio.no
+4722840208 ext. +47

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion